Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,030.00
-60.00 (-2.87%)
At close: Feb 6, 2026
Market Cap190.93B +56.2%
Revenue (ttm)12.77B +30.3%
Net Income-8.28B
EPS-152.96
Shares Out94.05M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume515,733
Average Volume809,245
Open2,060.00
Previous Close2,090.00
Day's Range1,964.00 - 2,060.00
52-Week Range1,080.00 - 2,530.00
Beta0.78
RSI46.34
Earnings Daten/a

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2023, Kangstem Biotech's revenue was 12.70 billion, a decrease of -22.06% compared to the previous year's 16.30 billion. Losses were -21.95 billion, 8.47% more than in 2022.

Financial Statements